Dr Lal PathLabs ne Q3 FY26 ke results announce kiye hain, aur revenue mein 10.6% ka solid jump dikhaya hai, jo ₹660 crore tak pahunch gaya. Pichhle 9 mahine mein bhi revenue 10.8% badh kar ₹2,060 crore ho gaya hai.
Asli baat ye hai ki per patient revenue toh 7.7% badh kar ₹927 ho gaya hai, jo kafi acchi baat hai. Lekin, overall patient volume growth quarter mein sirf 2.7% raha hai. Iski wajah ye hai ki seasonal fever tests kam ho gaye hain, jo normally is time mein volume badhate hain. Saalon mein patient volume growth abhi bhi 4.4% hai.
EBITDA ki baat karein toh, ek ₹30 crore ke exceptional item (jo labour code implementation ki wajah se tha) ko hata kar, EBITDA mein 16.3% ka growth dikha, jo ₹179 crore ho gaya. EBITDA margin 27.2% raha hai. Q3 mein Profit After Tax (PAT) thoda kam hua hai, 7.1% gir kar ₹91 crore raha, yeh bhi us exceptional item ki wajah se hai. Lekin 9 mahine ke liye PAT 12.2% badh kar ₹378 crore hua hai.
Company ek naya preventive health platform bhi launch kiya hai jiska naam 'Sovaaka' hai. Yeh ek strategic move hai curative se preventive healthcare ki taraf jaane ka. FY26 ke liye organic revenue growth ka target 11-12% rakha gaya hai.
FY26 mein CAPEX ₹150-160 crore ka plan hai. Aur company ke paas cash bhi accha hai, December end tak ₹1,411 crore ka net cash balance tha.